Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.
Also called NCT06759272
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose health services research
- Phase
- Phase 4
- Enrolled
- 120 participants
- Sponsor
- Nur Hafizah Annezah binti Utuh
- Registry
-
NCT06759272
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Malaysia
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06759272. Randomized; single masking; primary purpose health services research. Start 2025-02 (anticipated); primary completion 2026-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients
- Condition
- Coronary Arterial Disease (CAD (coronary artery disease))
- Condition
- ACS (Acute Coronary Syndrome)
- Condition
- SCAD
- Intervention (Genetic)
- CYP2C19 genotype-guided antiplatelet therapy
- Lead sponsor
- Nur Hafizah Annezah binti Utuh
Record details
- Record id
cardio:ct-nct06759272- Content hash
730473f0f93e9047277b2549173a55b8ab7db2b761d8ad5c099e4d2b0fe1dbac